Anti-CEACAM5 antibodies and uses thereof
AssigneeSanofi
InventorsPierre-Francois Berne, Francis Blanche, Hervé Bouchard, Béatrice Cameron, Tarik Dabdoubi, Stéphanie Decary, Paul Ferrari, Alexey Rak
Life of this patent
Estimating the term…
Abstract
Antibodies are provided which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also provided are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising the antibodies, or immunoconjugates. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.
Claims21
A method of treating a patient comprising administering to the patient an antibody or antigen binding fragment thereof which binds to human CEACAM5 (hCEACAM5) protein, wherein the patient has a hCEACAM5-expressing cancer, and wherein the antibody or antigen binding fragment thereof comprises:
- a) a CDR1-H comprising an amino acid sequence of SEQ ID NO:1;
- a CDR2-H comprising an amino acid sequence of SEQ ID NO:2;
- a CDR3-H comprising an amino acid sequence of SEQ ID NO:3;
- a CDR1-L comprising an amino acid sequence of SEQ ID NO:4;
- a CDR2-L comprising an amino acid sequence of SAS;
- and a CDR3-L comprising an amino acid sequence of SEQ ID NO:6;
- or
- b) a CDR1-H comprising an amino acid sequence of SEQ ID NO:7;
- a CDR2-H comprising an amino acid sequence of SEQ ID NO:8;
- a CDR3-H comprising an amino acid sequence of SEQ ID NO:9;
- a CDR1-L comprising an amino acid sequence of SEQ ID NO:10;
- a CDR2-L comprising an amino acid sequence of NTK or NTR;
- and a CDR3-L comprising an amino acid sequence of SEQ ID NO:12;
- or
- c) a CDR1-H comprising an amino acid sequence of SEQ ID NO:13;
- a CDR2-H comprising an amino acid sequence of SEQ ID NO:14;
- a CDR3-H comprising an amino acid sequence of SEQ ID NO:15;
- a CDR1-L comprising an amino acid sequence of SEQ ID NO:16;
- a CDR2-L comprising an amino acid sequence SAS;
- and a CDR3-L comprising an amino acid sequence of-SEQ ID NO:18;
- or
- d) a CDR1-H comprising an amino acid sequence of SEQ ID NO:19;
- a CDR2-H comprising an amino acid sequence of SEQ ID NO:20;
- a CDR3-H comprising an amino acid sequence of SEQ ID NO:21;
- a CDR1-L comprising an amino acid sequence of SEQ ID NO:22;
- a CDR2-L comprising an amino acid sequence of NAK;
- and a CDR3-L comprising an amino acid sequence of SEQID NO:24;
- or
- e) a CDR1-H comprising an amino acid sequence of SEQ ID NO:25;
- a CDR2-H comprising an amino acid sequence of SEQ ID NO:26;
- a CDR3-H comprising an amino acid sequence of SEQ ID NO:27;
- a CDR1-L comprising an amino acid sequence of SEQ ID NO:28;
- a CDR2-L of sequence NAK;
- and a CDR3-L comprising an amino acid sequence of SEQ ID NO:30.
A method of treating a patient comprising administering an immunoconjugate to the patient, wherein the immunoconjugate comprises an antibody or antigen binding fragment thereof linked to at least one growth inhibitory agent, wherein the patient has a hCEACAM5-expressing cancer, and wherein the antibody or antigen binding fragment thereof binds to human CEACAM5 protein and comprises:
- a) a CDR1-H comprising an amino acid sequence of SEQ ID NO:1;
- a CDR2-H comprising an amino acid sequence of SEQ ID NO:2;
- a CDR3-H comprising an amino acid sequence of SEQ ID NO:3;
- a CDR1-L comprising an amino acid sequence of SEQ ID NO:4;
- a CDR2-L comprising an amino acid sequence of SAS;
- and a CDR3-L comprising an amino acid sequence of SEQ ID NO:6;
- or
- b) a CDR1-H comprising an amino acid sequence of SEQ ID NO:7;
- a CDR2-H comprising an amino acid sequence of SEQ ID NO:8;
- a CDR3-H comprising an amino acid sequence of SEQ ID NO:9;
- a CDR1-L comprising an amino acid sequence of SEQ ID NO:10;
- a CDR2-L comprising an amino acid sequence of NTK or NTR;
- and a CDR3-L comprising an amino acid sequence of SEQ ID NO:12;
- or
- c) a CDR1-H comprising an amino acid sequence of SEQ ID NO:13;
- a CDR2-H comprising an amino acid sequence of SEQ ID NO:14;
- a CDR3-H comprising an amino acid sequence of SEQ ID NO:15;
- a CDR1-L comprising an amino acid sequence of SEQ ID NO:16;
- a CDR2-L comprising an amino acid sequence SAS;
- and a CDR3-L comprising an amino acid sequence of-SEQ ID NO:18;
- or
- d) a CDR1-H comprising an amino acid sequence of SEQ ID NO:19;
- a CDR2-H comprising an amino acid sequence of SEQ ID NO:20;
- a CDR3-H comprising an amino acid sequence of SEQ ID NO:21;
- a CDR1-L comprising an amino acid sequence of SEQ ID NO:22;
- a CDR2-L comprising an amino acid sequence of NAK;
- and a CDR3-L comprising an amino acid sequence of SEQ ID NO:24;
- or
- e) a CDR1-H comprising an amino acid sequence of SEQ ID NO:25;
- a CDR2-H comprising an amino acid sequence of SEQ ID NO:26;
- a CDR3-H comprising an amino acid sequence of SEQ ID NO:27;
- a CDR1-L comprising an amino acid sequence of SEQ ID NO:28;
- a CDR2-L of sequence NAK;
- and a CDR3-L comprising an amino acid sequence of SEQ ID NO:30.
A method of treating a patient comprising administering an immunoconjugate to the patient, wherein the immunoconjugate comprises an antibody linked to at least one growth inhibitory agent,
- wherein the patient has a hCEACAM5-expressing cancer,
- wherein the antibody binds to human CEACAM5 protein and comprises a heavy chain comprising the sequence of SEQ ID NO:87 and a light chain comprising the sequence of SEQ ID NO:88,
- wherein the antibody is covalently linked via N-succinimidyl pyridyldithiobutyrate (SPDB) to N2′-deacetyl-N-2′(4-methyl-4-mercapto-1-oxopentyl)-maytansine (DM4), and wherein the hCEACAM5-expressing cancer is selected from the group consisting of stomach, lung, pancreas, prostate and colorectal cancer.
Dependencies are inferred from the claim text.